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Abstract
Background: Earlier studies have mainly reported the use of antithrombotic drugs, beta-blockers
and statins among hospital patient populations or MI patients. This study aimed to describe the use
of these drugs among middle-aged Finnish coronary patients and to identify patient groups in risk
of being prescribed inadequate medication for secondary prevention of coronary heart disease.
Methods: One-year follow-up survey data from a random sample of a cohort of coronary patients
were used along with register data linked to the survey. The response rate was 54% (n = 2650).
The main outcome measures were use of antithrombotic drugs, beta-blockers and statins and the
data were analysed using logistic regression analysis.
Results: Among men and women, respectively, 82% and 81% used beta-blockers, 95% and 89%
used antithrombotic drugs, and 62% and 59% used statins. Younger men and men from higher
socioeconomic groups were more likely to use statins, even after controlling for disease severity
and comorbidity. In women, the age trend was reversed and no socioeconomic differences were
found. Drug use increased with increased disease severity, but diabetes had only a slight effect.
Conclusion: The use of antithrombotic drugs and beta-blockers among Finnish coronary patients
seemed to be rather appropriate and, to some extent, prescription practices of preventive
medication varied according to patients' risk of coronary events. However, statin use was
remarkably low among men with low socio-economic status, and there is need to improve
preventive drug treatment among diabetic coronary patients.
Background
Numerous randomised trials have shown that drugs for
reducing low density lipoprotein (LDL) cholesterol [1],
blood pressure [2], and platelet function [3] reduce the
incidence of vascular events, such as myocardial infarc-
tion (MI), non-fatal stroke and vascular death among high
risk individuals, including coronary heart disease (CHD)
patients. Combining aspirin or other antithrombotic
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is thus recommended for secondary prevention of CHD
[4]. These recommendations have also been published in
Finnish medical journals [5].
In 1995–1996 and in 1999–2000, the EUROASPIRE I and
II Group [6] examined the use of aspirin and other anti-
thrombotic drugs, beta-blockers, ACE-inhibitors and
lipid-lowering drugs, especially statins, in nine European
countries among a population of hospitalised coronary
patients aged 70 years or younger. For Finland they
reported a prevalence of 82% for antithrombotic drugs,
88% for beta-blockers and 63% for statins in 1999–2000.
Strandberg and colleagues [7] reported somewhat lower
levels of drug use among home-dwelling elderly (75+
years) coronary patients in Helsinki, Finland in 1998–
1999.
Use of services according to need and equal access to
health care are fundamental tenets of Finnish health pol-
icy [8]. Two dimensions of equity need to be taken into
account when evaluating the functioning of the health
care system in specific patient groups, such as coronary
heart disease patients, namely equal treatment of equals
(horizontal equity) and unequal treatment of unequals
(vertical equity) [e.g. [9]]. Earlier studies from other coun-
tries have reported gender and age differences in the prev-
alence of use of these drugs among MI patients [10,11]
and coronary patients in general [12]. The findings for
socioeconomic differences are inconsistent. Some studies
have reported socioeconomic disparities in the use of
these drugs [11], whereas others have found no differ-
ences [12]. Additionally, a recent ecological analysis of GP
prescribing practices has reported possible inequities in
prescribing rates on the basis of deprivation [13]. In Fin-
land both gender [14] and socioeconomic [15] differences
have been reported in the drug treatment of patients after
first MI. Male patients and those coming from higher soci-
oeconomic groups were more often prescribed beta-
blockers, antithrombotic drugs and cholesterol lowering
drugs at discharge from hospital than female patients and
those from lower socioeconomic groups. However,
Strandberg and colleagues [7] found no socioeconomic
differences in drug use among elderly Finnish coronary
patients.
Earlier studies have mainly reported the use of these drugs
among hospital patient populations or MI patients. The
aim of this study was to describe the use of aspirin and
other antithrombotic drugs, beta-blockers and statins
among middle-aged Finnish coronary patients. So as to
evaluate treatment during a stable phase of CHD, we ana-
lysed the use of these drugs in a random sample of coro-
nary patients diagnosed from six to seven years prior to
our survey. Since the study aimed to identify patient
groups in risk of being prescribed inadequate medication
for secondary prevention of CHD, it examined the use of
the drugs by gender, age, socioeconomic status, disease
history and severity, and CHD related comorbidity.
Methods
The Finnish drug reimbursement system
Use of medicines in Finnish outpatient care is financed by
the patients and the national sickness insurance scheme,
run by the Social Insurance Institution (SII). All inhabit-
ants are covered by the scheme, and annually around two-
thirds of the population get reimbursement. The share of
the scheme of the costs varies depending on the disease.
At the time of our survey, if the patient had a severe and
chronic illness he/she got a 100% or 75% reimbursement
instead of the basic 50%. Coronary heart disease belonged
to those diseases which entitled to 75% refund, if the cri-
teria set by the SII were met [16].
The study sample
A register of patients fulfilling special diagnostic criteria of
CHD and thereby eligible for special reimbursement of
medicine costs is maintained by the SII. The specific diag-
nostic criteria for inclusion are (1) chronic angina pectoris
symptoms responding to nitrates, and with unequivocal
ECG changes (if QS waves are not detected in resting ECG,
typical ischaemic changes are required in exercise test),
(2) diagnosed MI, (3) a performed revascularisation oper-
ation (coronary angioplasty or coronary artery bypass
grafting), or (4) CHD diagnosed in angiography. A certif-
icate written by a specialist in cardiology or internal med-
icine is required to evaluate whether the diagnostic criteria
have been met. In January 2001, 5009 Finnish speaking
persons aged between 45 and 74 years, and alive at that
time and entitled to special reimbursement of medication
costs due to CHD in 1994–1995 were drawn for the study
sample from the SII register. It was assumed that the treat-
ment situation would be stable among coronary patients
some years after the onset of the disease. To guarantee a
sufficient number of women, the study sample was first
evenly stratified by gender, and random sampling was
then applied within each gender group by hospital district
to ensure regional representativeness. Structured survey
questionnaires asking about sociodemographic back-
ground, CHD symptoms, disease history and severity,
treatment, comorbidity, and psychosocial factors were
sent to the study sample patients in February 2001.
Altogether 3 539 questionnaires were returned; 418 were
rejected due to incomplete data (missing values exceeding
20%), leaving 3 121 people in the study sample (62% of
the original sample). The baseline survey also asked the
participants to provide a written consent for combining
their questionnaire data with information about their use
of hospital services derived from the Hospital DischargePage 2 of 8
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sus data from Statistics Finland. Consent was given by
92% of the respondents. The one-year follow-up ques-
tionnaire was sent to respondents of the baseline survey in
February 2002. The response rate was 85% (54% of the
original sample), resulting in 2 650 respondents (Figure
1).
A separate analysis of non-response showed that women,
older persons and those with lower level of education
were more likely to be non-responders in the baseline and
those with lower level of education in the follow-up.
Weights were therefore calculated by gender, age (five-
year age groups) and level of education using logistic
regression analysis to correct the effect of non-response
both between the original sample and baseline respond-
ents and between baseline and follow-up. The study pro-
tocol was approved by the Research Ethics Committee of
STAKES.
Variables
The current analyses were based on answers to three ques-
tions on drug use in the follow-up survey. Use of beta-
blockers, antithrombotic drugs, and statins was analysed
separately for each drug group and for all three drug
groups combined, based on an open-ended question con-
cerning any prescription drugs used, and its name, dosage
and length of use (in days) during the follow-up year. Use
of aspirin and other antithrombotic drugs was addition-
ally based on answers to a question about over the coun-
ter drugs, plus a separate specific question on use of
aspirin or other antithrombotic drugs. Those reporting
use of antithrombotic drugs in any of these questions
were considered to be users of antithrombotic drugs. The
reported trade names were coded according to the Ana-
tomical Therapeutic Chemical (ATC) classification sys-
tem.
The independent variables were derived from the baseline
survey and from register data, which was individually
linked to the survey data using the personal identification
numbers by the relevant statistical authorities. The identi-
The flow chart of the study sampleFigure 1
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handing it to the research team. The sociodemographic var-
iables included gender, age, level of education, social
class, disposable income and hospital district of residence.
Disease history and severity were identified by use of short
term nitrates at least once a week, occurrence of MI, self-
assessed score for exertional chest pain following the New
York Heart Association classification, and history of coro-
nary revascularisation. CHD-related comorbidity included
heart failure and diabetes.
Information about gender and age came from SII and
level of education from census data for the year 2000 from
Statistics Finland. Education was measured as level of edu-
cational achievement, high corresponding to 12 or more
years of education, intermediate to 10–11 years, and basic
to nine years or less. Data on social class were derived
from census data for 2000, and for those outside the
labour market from longitudinal census data covering
1970–1995. Family disposable income was derived from
census and national tax register data for 2000 and
adjusted for family size using the OECD equivalence
scale. For statistical analyses income thirds were calcu-
lated. Data on hospital district was derived from the 2000
census. Data on hospitalisation due to MI and revascular-
isation operations in 1990–2001 were derived from the
Finnish Hospital Discharge Register for those who con-
sented to the combining of their register and self-reported
data (92%). Self-reported information was used for the
remainder. The rest of the variables were based on the
baseline questionnaire. The chest pain question asked
respondents to assess, whether they had exertional chest
pain 1 = not at all or only on heavy straining, 2 = walking
uphill or ascending stairs, 3 = walking on the level, or 4 =
also while resting. A dichotomous variable for exertional
chest pain was computed by combining options 2–4.
Statistical methods
Age standardised proportions were estimated by logistic
regression analysis using the predictive margins approach
[17]. In this approach, adjusted proportions can be inter-
preted as the expected response for the individual in
group r as an average predicted response if everyone in the
sample had been in group r. Graubard and Korn [17] have
generalised the predictive margins approach to non-linear
cases, which was used in this study. The total sample was
used as the standard population. Logistic regression anal-
ysis was also used to analyse the possible effect of the
independent variables on drug use, controlling for age
only, and age and all other independent variables. Sepa-
rate models were estimated using the SAS software for the
three drug groups and their combination, and men and
women were analysed separately. Models were estimated
for each of the socioeconomic variables, but since the
results were similar with each of them, only the models by
income are presented. Since the multivariate analyses pro-
duced similar results to the models controlling only for
age, only the latter are presented. The results are presented
as odds ratios and their 95% confidence intervals.
Results
There were small variations in the use of beta-blockers,
antithrombotic drugs and statins between men and
women (Table 1); however, women used antithrombotic
drugs significantly less often than men. Half of both men
and women reported using all three of these drug catego-
ries, and a further 36% of men and 33% of women
reported use of two of them, mainly antithrombotic drugs
and beta-blockers. If use of only one drug type was
reported, antithrombotics were the most common. Table
1 also presents figures for the use of each drug by all inde-
pendent variables.
Among men, age and socioeconomic patterns were found
in the use of these drugs (Table 2): younger men and those
from higher socioeconomic groups had higher odds for
drug use. However, these differences only reached statisti-
cal significance for statin use and, for the age pattern, in
use of all three drug types combined. Among women the
age pattern was reversed, but did not reach statistical sig-
nificance except for statins. No socioeconomic disparities
were found among women. Use of nitrates, diabetes or
heart failure did not affect drug use among either gender.
Men with exertional chest pain were more likely to use
beta-blockers than others, while among women the pat-
tern was similar for each of these drugs, but did not reach
statistical significance. In both genders, MI patients and
patients who had undergone a revascularisation opera-
tion had higher odds for the use of each of these drugs and
of all three combined.
When simultaneously controlling for age, socioeconomic
status, disease history and severity, and comorbidity, few
changes were detected in the results. The age pattern
remained practically unchanged for men, and lost statisti-
cal significance among women. Socioeconomic differ-
ences remained unchanged in both genders. This was also
true for nitrate use and comorbidity among both men and
women and for men reporting exertional chest pain.
However, among women reporting exertional chest pain,
the increased use of beta-blockers (OR 1.45, 95% CI 1.03
to 2.04), statins (OR 1.37, 95% CI 1.03 to 1.83) and all
three of these drugs (OR 1.50, 95% CI 1.13 to 1.99)
reached statistical significance. Results for history of revas-
cularisation remained similar for both genders and for MI
among men; among women MI only reached statistical
significance in antithrombotic drug use (OR 2.97, 95% CI
1.53 to 5.80).Page 4 of 8
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of revascularisation on drug use, a statistically significant
interaction was found among men in the combined use of
all three of these drug types. Among MI men, the effect of
a history of revascularisation on drug use was smaller (OR
1.64 95% CI 1.16 to 2.32) than among non-MI men (OR
3.03 95% CI 2.24 to 4.09). Among women, revascularisa-
tion only had an effect in antithrombotic drug use among
non-MI women (OR 9.25, 95% CI 3.36 to 25.5).
Discussion
The levels of use of antithrombotic drugs, beta-blockers
and statins by Finnish patients with established CHD
were largely appropriate, but some interesting subgroup
differences emerged. The levels of drug use in the present
study are similar to earlier findings in Finland [6],
although somewhat lower than those reported in EUROA-
SPIRE II and somewhat higher than in the study of home-
dwelling elderly in Helsinki. There was also an especially
markable difference in the use of statins compared to the
study by Strandberg and colleagues [7]. These differences
are probably due to differences in the study populations
and time periods. Our analyses were based on a randomly
sampled cohort of coronary patients whereas EUROA-
SPIRE II analysed hospital patient (MI, coronary revascu-
larisation, or hospital care due to myocardial ischaemia)
populations. However, it should be noted that patients in
our study had established disease according to at least
some objective criteria; those with symptoms but without
objective evidence of CHD were not included. The popu-
lation studied by Strandberg and colleagues [7] was much
older than ours. Moreover, coronary patients first quali-
fied for extra reimbursement for statins in 2000, after the
Strandberg study.
Drug use decreased with age among men, but the reverse
was found among women. Whether these findings indi-
cate less than appropriate health care among older men
and excess care among older women is difficult to inter-
pret. The former interpretation may imply the need for
more efficient care for elderly men. In line with earlier
results [e.g. [12,18]] the likelihood of drug use tended to
grow with increased disease severity, although the differ-
ences were statistically significant in only a few subgroups.
Thus patients with past MI and history of coronary revas-
cularisation, and women with exertional chest pain were
more likely to use drugs. Patients with known diabetes
also used somewhat more drugs than non-diabetic
patients, but the differences were not statistically signifi-
cant. The fate of coronary patients with diabetes is known
to be more serious than that of patients without diabetes
[19]. If the present results indicate that Finnish doctors do
not consider that diabetes justifies more effective drug
treatment of coronary patients, then more physician edu-
cation is needed.
There were no marked disparities in use of antithrombotic
drugs or beta-blockers by socioeconomic indicators. How-
ever, after controlling for age, disease history and severity,
and comorbity, socioeconomic differences persisted
among men in statin use. There could be several reasons
for this: whereas aspirin and beta-blockers are relatively
Table 1: Use of antithrombotic drugs, beta-blockers and statins among men and women. 
All three drugs Antithrombotics Betablockers Statins n
Men Women Men Women Men Women Men Women Men Women
Total 51.6 49.1 93.3 89.1 81.8 80.6 62.1 58.6 1429 1221
Age (years) 45–54 59.6 45.2 95.0 85.0 86.2 77.4 69.3 52.7 218 93
55–64 54.4 46.0 94.1 87.6 82.5 79.8 65.8 55.0 594 411
65–74 46.2 51.3 91.9 90.5 79.6 81.5 56.1 61.4 617 717
Income third highest 55.4 48.0 93.7 89.4 81.8 80.3 68.2 55.1 519 303
intermed 48.6 51.9 94.4 89.0 82.3 81.7 58.7 61.9 456 366
lowest 50.0 50.1 92.0 89.0 81.8 80.9 57.3 60.1 353 468
MI no 47.9 47.1 91.7 87.5 79.6 79.2 58.9 56.7 792 916
yes 55.3 57.2 95.5 95.1 85.1 85.1 64.5 66.4 613 276
Use of less 51.0 48.4 93.3 89.1 81.9 81.0 61.4 57.8 1211 953
nitrates ≥ 1/week 52.9 53.4 92.6 90.2 82.6 79.4 61.4 62.5 194 246
Chest pain no 51.8 46.5 94.1 88.5 80.0 78.3 63.6 57.0 738 391
yes 51.6 50.8 93.1 89.6 84.2 81.7 60.5 60.1 623 758
Diabetes no 51.3 48.6 92.9 89.0 81.1 80.8 61.9 58.3 1232 1056
yes 49.9 54.2 95.0 91.0 86.9 81.1 57.7 62.9 197 165
Heart no 51.7 49.6 93.4 89.4 82.0 80.7 62.4 59.3 1129 962
failure yes 48.9 48.6 92.3 89.1 81.5 81.3 57.3 57.6 300 259
Revascularisation no 41.7 40.9 90.5 86.4 80.3 77.9 51.4 51.1 738 891
yes 61.7 72.9 96.0 97.2 83.8 88.4 72.4 80.4 683 322
Age group specific and age-standardised prevalence percentages by income, disease history and severity, and comorbidities.Page 5 of 8
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bursement rate – remain more costly for the individual
patient, which may explain the lower statin use among
less affluent groups. Moreover, the tradition of using anti-
thrombotic drugs and beta-blockers among coronary
patients is much longer than for statins. On the other
hand, earlier studies both in Finland and elsewhere have
reported more effective treatment of CHD among higher
socioeconomic groups, including thrombolytic treatment
after MI [15] and revascularisation operations after MI
[15,20,21] and among coronary patients in general
[22,23]. As our analysis was based on questionnaire infor-
mation, no laboratory examination data were available on
possible differences in serum cholesterol levels between
socioeconomic groups. However, we were unable to find
any Finnish studies reporting higher serum cholesterol
levels among more affluent men. Instead, Finnish
research has consistently reported higher serum choles-
terol levels among lower socioeconomic groups [24].
Our results nevertheless fail to clarify whether socioeco-
nomic differences in statin use are due to physicians' une-
ven prescription practices or variation in patients'
compliance with drug treatment. Several Finnish studies
have reported healthier behaviours among higher socioe-
conomic groups both in terms of dietary fat use and lei-
sure time physical exercise [25].
Earlier studies on hormone replacement therapy and anti-
hypertensive medication have suggested area variation in
drug use [26,27]. Area differences especially in secondary
prevention practices could have an effect on socioeco-
nomic differences found in our CHD cohort. We carried
out additional analysis (random effects model, SAS 8e
Table 2: Use of antithrombotic drugs, statins and beta-blockers among Finnish CHD-patients in 2001.
MEN All three Antithrombotic
drugs
Beta-blockers Statins
OR 95% CI p value OR 95% CI p = OR 95% CI p value OR 95% CI p value
Age 45–54 1.00 1.00 1.00 1.00
55–64 0.80 0.58 – 1.11 0.83 0.40 – 1.72 0.71 0.45 – 1.13 0.87 0.62 – 1.23
65–74 0.57 0.41 – 0.79 <0.001 0.59 0.30 – 1.18 ns 0.59 0.37 – 0.93 ns 0.57 0.41 – 0.80 <0.001
Income highest 1.00 1.00 1.00 1.00
third intermed 0.77 0.58 – 1.01 1.16 0.65 – 2.06 1.05 0.74 – 1.50 0.68 0.51 – 0.90
lowest 0.81 0.60 – 1.08 ns 0.73 0.42 – 1.29 ns 1.00 0.68 – 1.45 ns 0.64 0.47 – 0.87 <0.01
AMI no 1.00 1.00 1.00 1.00
yes 1.34 1.08 – 1.67 <0.01 1.89 1.17 – 3.04 <0.01 1.45 1.09 – 1.95 <0.05 1.26 1.01 – 1.58 <0.05
Use of less 1.00 1.00 1.00 1.00
nitrates ≥ 1/week 1.09 0.80 – 1.48 ns 0.91 0.50 – 1.64 ns 1.05 0.70 – 1.57 ns 1.00 0.73 – 1.38 ns
Chest pain no 1.00 1.00 1.00 1.00
yes 1.00 0.80 – 1.25 ns 0.85 0.54 – 1.33 ns 1.35 1.01 – 1.80 <0.05 0.88 0.70 – 1.11 ns
Diabetes no 1.00 1.00 1.00 1.00
yes 0.95 0.69 – 1.29 ns 1.48 0.74 – 2.94 ns 1.56 1.00 – 2.44 ns 0.83 0.61 – 1.14 ns
Heart no 1.00 1.00 1.00 1.00
failure yes 0.89 0.69 – 1.16 ns 0.85 0.52 – 1.39 ns 0.97 0.69 – 1.36 ns 0.81 0.62 – 1.06 ns
Revasc. no 1.00 1.00 1.00 1.00
yes 2.26 1.81 – 2.82 <0.0001 2.57 1.60 – 4.13 0.0001 1.27 0.96 – 1.68 ns 2.48 1.97 – 3.13 <0.0001
WOMEN All three Antithrombotic
 drugs
Beta-blockers Statins
OR 95% CI p value OR 95% CI p value OR 95% CI p value OR 95% CI p value
Age 45–54 1.00 1.00 1.00 1.00
55–64 1.07 0.68 – 1.67 1.17 0.61 – 2.23 1.18 0.69 – 2.02 1.11 0.71 – 1.74
65–74 1.31 0.86 – 2.01 ns 1.58 0.85 – 2.95 ns 1.31 0.78 – 2.18 ns 1.46 0.95 – 2.23 <0.01
Income highest 1.00 1.00 1.00 1.00
third intermed 1.14 0.83 – 1.55 0.94 0.58 – 1.54 1.06 0.72 – 1.57 1.29 0.94 – 1.77
lowest 1.05 0.78 – 1.42 ns 0.95 0.59 – 1.54 ns 1.01 0.70 – 1.47 ns 1.18 0.88 – 1.60 ns
AMI no 1.00 1.00 1.00 1.00
yes 1.51 1.16 – 1.97 <0.01 2.79 1.60 – 4.89 <0.001 1.51 1.06 – 2.15 <0.05 1.52 1.16 – 2.00 <0.01
Use of less 1.00 1.00 1.00 1.00
nitrates ≥ 1/week 1.21 0.92 – 1.59 ns 1.11 0.71 – 1.76 ns 0.90 0.64 – 1.27 ns 1.20 0.91 – 1.59 ns
Chest pain no 1.00 1.00 1.00 1.00
yes 1.19 0.93 – 1.51 ns 1.14 0.78 – 1.67 ns 1.25 0.93 – 1.68 ns 1.13 0.89 – 1.44 ns
Diabetes no 1.00 1.00 1.00 1.00
yes 1.27 0.93 – 1.75 ns 1.26 0.73 – 2.19 ns 1.03 0.69 – 1.54 ns 1.23 0.89 – 1.71 ns
Heart no 1.00 1.00 1.00 1.00
failure yes 0.94 0.72 – 1.23 ns 0.96 0.62 – 1.48 ns 1.03 0.73 – 1.45 ns 0.92 0.70 – 1.20 ns
Revasc. no 1.00 1.00 1.00 1.00
yes 3.92 2.99 – 5.15 <0.0001 5.55 2.84 – 10.8 <0.0001 2.16 1.50 – 3.11 <0.0001 3.96 2.95 – 5.33 <0.0001
Models for use of each drug controlling only for age, five-year age bands. Odds ratios (OR) and their 95% confidence intervals (CI)Page 6 of 8
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regional differences between 20 hospital districts in our
results. However, the analysis showed no area effect.
A strength of our study is that it was based on a random
sample from a cohort of coronary patients and not merely
hospitalised patients. Additionally, the specific criteria
used for defining CHD and the approval procedure for
special entitlements would have minimised false positive
cases. There are some factors, however, that might poten-
tially bias our findings on socioeconomic differences in
drug use. First, a possible source of bias is multiple com-
parisons which could have produced false positive results
by chance. Since our results were systematic by all the
socioeconomic variables, this is unlikely to be the case.
Another issue is selective mortality which is likely to have
resulted in fewer respondents from lower socioeconomic
groups due to higher mortality before hospitalisation and
higher case-fatality from first coronary events [15]. More-
over, in our data those with lower level of education were
more likely than others to be non-respondents. To correct
the potential bias introduced by selective non-response,
weights were calculated to our data. However, weighting
assumes that the drug use of respondents and non-
respondents is similar within these groups, which may
not be the case. Due to selective mortality and the distri-
bution of non-responders, it seems obvious that our
results give a conservative estimate of socioeconomic dif-
ferences rather than an overestimate. This conclusion is
supported by an additional analysis of non-response
using SII drug register data which revealed that non-
respondents were less likely to have had medicine costs
for statins (OR = 0.66, 95% CI 0.59 to 0.75) and beta-
blockers (OR = 0.82, 95% CI 0.71 to 0.94) reimbursed
during 2000 than respondents. No differences were found
between respondents and non-respondents in reimburse-
ments for nitrates (OR = 0.92, 95% CI 0.81 to 1.04). This
selective non-response means that our estimates for prev-
alence of beta-blocker and statin use are probably some-
what optimistic. A third potential source of bias is that
other than CHD related comorbidity – which is likely to
be more prevalent among lower socioeconomic groups –
was not controlled for. Since statins are not reported to
have major interaction effects with other drugs, the possi-
ble mechanism could be either the need to control the
total amount of drugs used or high total drug costs. The
effect of non-CHD related morbidity on statin use
remains an important issue for further analysis. A fourth
potential source of bias is recall bias in reporting drug use.
We were not able to analyse the impact of recall bias in
detail because we did not have register information on
medicine use in our data. However, we do not expect there
to be systematic socioeconomic bias, since earlier studies
have reported high reliability and validity in survey self-
reports of medicine use [28].
Conclusion
According to our results about 50% of Finnish coronary
heart disease patients used all three medications, anti-
thrombotic agents, beta-blockers and statins, for prevent-
ing new coronary events. We were not able to use clinical
information for assessing the appropriateness of the indi-
vidual patients' treatment but the results seem to indicate
a need to evaluate the practices to prescribe statins for cor-
onary heart disease patients. In terms of horizontal equity,
socioeconomic differences were observed in statin use
possibly indicating more efficient care of more affluent
patients or a longer seeding period in the care pattern of
less affluent patients with this expensive mode of treat-
ment. In terms of vertical equity more emphasis should
evidently be paid to some subgroups, such as diabetic
patients in order to improve their care.
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